By Melissa Lipman ( November 23, 2015, 8:43 PM EST) -- Pfizer's $160 billion bid to acquire Irish drugmaker Allergan will surely attract considerable government attention, but despite its eye-popping size, antitrust issues are unlikely to fell the deal given the way officials look at pharmaceutical mergers on a drug-by-drug basis....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.